Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis.
Hyperkeratotic-type tinea pedis is chronic and recalcitrant to topical antifungal agents. Some topical antifungal agents are effective; however, long duration of therapy is required, which often reduce the treatment compliance of patients. To seek for short period therapy of hyperkeratotic type tinea pedis, in this study, we observed the efficacy and safety of treatment of topical terbinafine and 10% urea ointment combined oral terbinafine. Participants with hyperkeratotic type tinea pedis were randomly assigned to two groups. Patients in group I were treated with oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks, whereas in group II, only the above topical agents were applied for 12 weeks. Clinical improvement rates and fungal eradication rates were compared between the two groups at 24 weeks after the initiation of treatment. The group I had stopped the topical therapy 8 weeks earlier than group II. There were no significant differences in mycological eradication rates and clinical improvement rates between the two groups, besides, no major side effects were noted in both groups. The short combination therapy with oral terbinafine was effective and safe; it should be a valuable option for patients with hyperkeratotic type tinea pedis.
Department of Dermatology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Dermatology, People's Hospital of Zhengzhou, Zhengzhou, China.
Tian-Wei
TW
Shi
Jiang-An
JA
Zhang
Xian-Wei
XW
Zhang
Hong-Xing
HX
Yu
Yong-Bo
YB
Tang
Jian-Bin
JB
Yu
D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D009824:Ointments / Q000008:administration & dosage; D011446:Prospective Studies; D000077291:Terbinafine; D014008:Tinea Pedis / Q000188:drug therapy*; D016896:Treatment Outcome; D014508:Urea / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
D000935:Antifungal Agents; D009281:Naphthalenes; D009824:Ointments; D014508:Urea; D000077291:Terbinafine
Terbinafine; hyperkeratotic type; tinea pedis; treatment; urea ointment